Novo Nordisk AS
NOV
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
77,406
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,771.10 | 3.90 | -0.04% |
| CAC 40 | 7,681.76 | 60.48 | -0.78% |
| DAX 40 | 23,488.86 | 210.26 | -0.89% |
| Dow JONES (US) | 42,473.23 | 41.86 | -0.10% |
| FTSE 100 | 8,838.21 | 37.01 | -0.42% |
| HKSE | 23,980.30 | 80.69 | -0.34% |
| NASDAQ | 19,634.18 | 67.03 | -0.34% |
| Nikkei 225 | 38,536.74 | 225.41 | 0.59% |
| NZX 50 Index | 12,639.35 | 50.78 | -0.40% |
| S&P 500 | 6,018.71 | 14.40 | -0.24% |
| S&P/ASX 200 | 8,541.30 | 7.10 | -0.08% |
| SSE Composite Index | 3,387.40 | 1.32 | -0.04% |